Sign In
Buy DTCFF
$0.299
+0.0178 (+6.31%)
At Close: Jul 31, 2026
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develop
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
03:15am, Tuesday, 14'th May 2024
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develop
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
03:15am, Wednesday, 01'st May 2024
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company develop
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
03:15am, Tuesday, 23'rd Apr 2024
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company devel
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
03:15am, Wednesday, 17'th Apr 2024
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company devel
Defence Therapeutics Announces Warrant Terms Amendment
06:00pm, Friday, 05'th Apr 2024
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology c
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
03:15am, Tuesday, 26'th Mar 2024
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developin
Defence Completes 2nd Tranche of Financing
06:30pm, Friday, 22'nd Mar 2024
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
03:15am, Monday, 04'th Mar 2024
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develo
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
06:00pm, Thursday, 29'th Feb 2024
Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnolo
Defence Therapeutics Completes 1st Tranche of Financing
08:00pm, Tuesday, 30'th Jan 2024
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnolo
Defence Financing
07:30pm, Friday, 19'th Jan 2024
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnolo
Defence Begins Trading on the OTCQB and Arranges Financing
07:15pm, Friday, 12'th Jan 2024
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnolo
Defence's AccuTOX(R) Impairs Lung Cancer Growth
03:15am, Wednesday, 10'th Jan 2024
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnol
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
03:15am, Tuesday, 12'th Dec 2023
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechn
